Changeflow GovPing Pharma & Drug Safety Patent EP3690038A1: Antibody Pyrrolidobenzodiaz...
Routine Notice Added Final

Patent EP3690038A1: Antibody Pyrrolidobenzodiazepine Derivative Conjugate

Favicon for changeflow.com ChangeBridge: EPO Bulletin - Peptides (C07K)
Published March 11th, 2026
Detected March 25th, 2026
Email

Summary

The European Patent Office has published patent application EP3690038A1 for an "Antibody Pyrrolidobenzodiazepine Derivative Conjugate" filed by Daiichi Sankyo Company, Limited. This publication relates to a new class of therapeutic compounds.

What changed

The European Patent Office (EPO) has published patent application EP3690038A1, titled "Antibody Pyrrolidobenzodiazepine Derivative Conjugate." The application was filed by Daiichi Sankyo Company, Limited, and lists multiple inventors. This publication signifies the formal disclosure of the patent application, detailing the invention related to antibody-drug conjugates.

This patent publication is primarily an informational disclosure. For compliance officers in the pharmaceutical sector, it highlights ongoing innovation and potential future therapeutic developments. While this publication does not impose immediate compliance obligations, it is relevant for competitive intelligence and understanding the intellectual property landscape in oncology drug development. No specific compliance actions or deadlines are associated with this patent publication itself.

Source document (simplified)

← EPO Patent Bulletin

ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE

Publication EP3690038A1 Kind: A1 Mar 11, 2026

Applicants

Daiichi Sankyo Company, Limited

Inventors

TODA Narihiro, OTA Yusuke, DOI Fuminao, MEGURO Masaki, HAYAKAWA Ichiro, ASHIDA Shinji, MASUDA Takeshi, NAKADA Takashi, IWAMOTO Mitsuhiro, HARADA Naoya, TERAUCHI Tomoko, OKAJIMA Daisuke, NAKAMURA Kensuke, UCHIDA Hiroaki, HAMADA Hirofumi

IPC Classifications

A61K 31/5513 20060101AFI20260205BHEP A61K 39/395 20060101ALI20260205BHEP A61K 47/68 20170101ALI20260205BHEP A61P 35/00 20060101ALI20260205BHEP C07D 519/00 20060101ALI20260205BHEP C07K 16/1203 20260101ALI20260205BHEP C07K 16/18 20060101ALI20260205BHEP C07K 16/28 20060101ALI20260205BHEP C07K 16/32 20060101ALI20260205BHEP C07K 16/00 20060101ALI20260205BHEP C07K 16/30 20060101ALI20260205BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Named provisions

ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE

Source

Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
EPO
Published
March 11th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
EP3690038A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug Development Patent Filing
Geographic scope
European Union EU

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Compliance frameworks
FDA 21 CFR Part 11 GxP
Topics
Intellectual Property Drug Development

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: EPO Bulletin - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.